Cargando…

An integrative analysis revealing cuproptosis-related lncRNAs signature as a novel prognostic biomarker in hepatocellular carcinoma

Background: Cuproptosis is a newly defined form of cell death, whether cuproptosis involved in hepatocellular carcinoma (HCC) remains elusive. Method: We obtained patients’ RNA expression data and follow-up information from University of California Santa Cruz (UCSC) and The Cancer Genome Atlas (TCGA...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xilang, Sun, Mengyu, Feng, Weibo, Chen, Jie, Ji, Xiaoyu, Xie, Meng, Huang, Wenjie, Chen, Xiaoping, Zhang, Bixiang, Nie, Yongzhan, Fan, Daiming, Wu, Kaichun, Xia, Limin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9950118/
https://www.ncbi.nlm.nih.gov/pubmed/36845390
http://dx.doi.org/10.3389/fgene.2023.1056000
_version_ 1784893093149933568
author Chen, Xilang
Sun, Mengyu
Feng, Weibo
Chen, Jie
Ji, Xiaoyu
Xie, Meng
Huang, Wenjie
Chen, Xiaoping
Zhang, Bixiang
Nie, Yongzhan
Fan, Daiming
Wu, Kaichun
Xia, Limin
author_facet Chen, Xilang
Sun, Mengyu
Feng, Weibo
Chen, Jie
Ji, Xiaoyu
Xie, Meng
Huang, Wenjie
Chen, Xiaoping
Zhang, Bixiang
Nie, Yongzhan
Fan, Daiming
Wu, Kaichun
Xia, Limin
author_sort Chen, Xilang
collection PubMed
description Background: Cuproptosis is a newly defined form of cell death, whether cuproptosis involved in hepatocellular carcinoma (HCC) remains elusive. Method: We obtained patients’ RNA expression data and follow-up information from University of California Santa Cruz (UCSC) and The Cancer Genome Atlas (TCGA). We analyzed the mRNA level of Cuproptosis-related genes (CRGs) and performed univariate Cox analysis. Liver hepatocellular carcinoma (LIHC) was chosen for further investigation. Real-Time quantitative PCR (RT-qPCR), Western blotting (WB), Immunohistochemical (IHC), and Transwell assays were used to determine expression patterns and functions of CRGs in LIHC. Next, we identified CRGs-related lncRNAs (CRLs) and differentially expressed CRLs between HCC and normal cases. Univariate Cox analysis, least absolute shrinkage selection operator (LASSO) analysis and Cox regression analysis were used to construct the prognostic model. Univariate and multivariate Cox analysis was used to assess whether the risk model can act as an independent risk factor of overall survival duration. Different risk groups performed immune correlation analysis, tumor mutation burden (TMB), and Gene Set Enrichment Analysis (GSEA) analysis were performed in different risk groups. Finally, we assessed the performance of the predictive model in drug sensitivity. Results: CRGs expression levels have significant differences between tumor and normal tissues. High expression of Dihydrolipoamide S-Acetyltransferase (DLAT) correlated to metastasis of HCC cells and indicated poor prognosis for HCC patients. Our prognostic model consisted of four cuproptosis-related lncRNA (AC011476.3, AC026412.3, NRAV, MKLN1-AS). The prognostic model performed well in predicting survival rates. The results from Cox regression analysis suggested that risk score can serve as an independent prognostic element for survival durations. Survival analysis revealed that low risk patients have extended survival periods compared with those with high risk. The results of the immune analysis indicated that risk score has a positive correlation with B cell and CD4(+) T cell Th2, while has a negative relationship with endothelial cell and hematopoietic cells. Besides, immune checkpoint genes have higher expression folds in the high-risk set than in the low-risk set. The high-risk group had higher rates of genetic mutation than the low-risk set while having a shorter survival time. GSEA revealed the signaling pathways enriched in the high-risk group were mostly immune-related, while metabolic-related pathways were enriched in the low-risk group. Drugs sensitivity analysis indicated that our model has the ability to predict the efficacy of clinical treatment. Conclusion: The Cuproptosis-related lncRNAs prognostic formula is a novel predictor of HCC patients’ prognosis and drug sensitivity.
format Online
Article
Text
id pubmed-9950118
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-99501182023-02-25 An integrative analysis revealing cuproptosis-related lncRNAs signature as a novel prognostic biomarker in hepatocellular carcinoma Chen, Xilang Sun, Mengyu Feng, Weibo Chen, Jie Ji, Xiaoyu Xie, Meng Huang, Wenjie Chen, Xiaoping Zhang, Bixiang Nie, Yongzhan Fan, Daiming Wu, Kaichun Xia, Limin Front Genet Genetics Background: Cuproptosis is a newly defined form of cell death, whether cuproptosis involved in hepatocellular carcinoma (HCC) remains elusive. Method: We obtained patients’ RNA expression data and follow-up information from University of California Santa Cruz (UCSC) and The Cancer Genome Atlas (TCGA). We analyzed the mRNA level of Cuproptosis-related genes (CRGs) and performed univariate Cox analysis. Liver hepatocellular carcinoma (LIHC) was chosen for further investigation. Real-Time quantitative PCR (RT-qPCR), Western blotting (WB), Immunohistochemical (IHC), and Transwell assays were used to determine expression patterns and functions of CRGs in LIHC. Next, we identified CRGs-related lncRNAs (CRLs) and differentially expressed CRLs between HCC and normal cases. Univariate Cox analysis, least absolute shrinkage selection operator (LASSO) analysis and Cox regression analysis were used to construct the prognostic model. Univariate and multivariate Cox analysis was used to assess whether the risk model can act as an independent risk factor of overall survival duration. Different risk groups performed immune correlation analysis, tumor mutation burden (TMB), and Gene Set Enrichment Analysis (GSEA) analysis were performed in different risk groups. Finally, we assessed the performance of the predictive model in drug sensitivity. Results: CRGs expression levels have significant differences between tumor and normal tissues. High expression of Dihydrolipoamide S-Acetyltransferase (DLAT) correlated to metastasis of HCC cells and indicated poor prognosis for HCC patients. Our prognostic model consisted of four cuproptosis-related lncRNA (AC011476.3, AC026412.3, NRAV, MKLN1-AS). The prognostic model performed well in predicting survival rates. The results from Cox regression analysis suggested that risk score can serve as an independent prognostic element for survival durations. Survival analysis revealed that low risk patients have extended survival periods compared with those with high risk. The results of the immune analysis indicated that risk score has a positive correlation with B cell and CD4(+) T cell Th2, while has a negative relationship with endothelial cell and hematopoietic cells. Besides, immune checkpoint genes have higher expression folds in the high-risk set than in the low-risk set. The high-risk group had higher rates of genetic mutation than the low-risk set while having a shorter survival time. GSEA revealed the signaling pathways enriched in the high-risk group were mostly immune-related, while metabolic-related pathways were enriched in the low-risk group. Drugs sensitivity analysis indicated that our model has the ability to predict the efficacy of clinical treatment. Conclusion: The Cuproptosis-related lncRNAs prognostic formula is a novel predictor of HCC patients’ prognosis and drug sensitivity. Frontiers Media S.A. 2023-02-10 /pmc/articles/PMC9950118/ /pubmed/36845390 http://dx.doi.org/10.3389/fgene.2023.1056000 Text en Copyright © 2023 Chen, Sun, Feng, Chen, Ji, Xie, Huang, Chen, Zhang, Nie, Fan, Wu and Xia. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Genetics
Chen, Xilang
Sun, Mengyu
Feng, Weibo
Chen, Jie
Ji, Xiaoyu
Xie, Meng
Huang, Wenjie
Chen, Xiaoping
Zhang, Bixiang
Nie, Yongzhan
Fan, Daiming
Wu, Kaichun
Xia, Limin
An integrative analysis revealing cuproptosis-related lncRNAs signature as a novel prognostic biomarker in hepatocellular carcinoma
title An integrative analysis revealing cuproptosis-related lncRNAs signature as a novel prognostic biomarker in hepatocellular carcinoma
title_full An integrative analysis revealing cuproptosis-related lncRNAs signature as a novel prognostic biomarker in hepatocellular carcinoma
title_fullStr An integrative analysis revealing cuproptosis-related lncRNAs signature as a novel prognostic biomarker in hepatocellular carcinoma
title_full_unstemmed An integrative analysis revealing cuproptosis-related lncRNAs signature as a novel prognostic biomarker in hepatocellular carcinoma
title_short An integrative analysis revealing cuproptosis-related lncRNAs signature as a novel prognostic biomarker in hepatocellular carcinoma
title_sort integrative analysis revealing cuproptosis-related lncrnas signature as a novel prognostic biomarker in hepatocellular carcinoma
topic Genetics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9950118/
https://www.ncbi.nlm.nih.gov/pubmed/36845390
http://dx.doi.org/10.3389/fgene.2023.1056000
work_keys_str_mv AT chenxilang anintegrativeanalysisrevealingcuproptosisrelatedlncrnassignatureasanovelprognosticbiomarkerinhepatocellularcarcinoma
AT sunmengyu anintegrativeanalysisrevealingcuproptosisrelatedlncrnassignatureasanovelprognosticbiomarkerinhepatocellularcarcinoma
AT fengweibo anintegrativeanalysisrevealingcuproptosisrelatedlncrnassignatureasanovelprognosticbiomarkerinhepatocellularcarcinoma
AT chenjie anintegrativeanalysisrevealingcuproptosisrelatedlncrnassignatureasanovelprognosticbiomarkerinhepatocellularcarcinoma
AT jixiaoyu anintegrativeanalysisrevealingcuproptosisrelatedlncrnassignatureasanovelprognosticbiomarkerinhepatocellularcarcinoma
AT xiemeng anintegrativeanalysisrevealingcuproptosisrelatedlncrnassignatureasanovelprognosticbiomarkerinhepatocellularcarcinoma
AT huangwenjie anintegrativeanalysisrevealingcuproptosisrelatedlncrnassignatureasanovelprognosticbiomarkerinhepatocellularcarcinoma
AT chenxiaoping anintegrativeanalysisrevealingcuproptosisrelatedlncrnassignatureasanovelprognosticbiomarkerinhepatocellularcarcinoma
AT zhangbixiang anintegrativeanalysisrevealingcuproptosisrelatedlncrnassignatureasanovelprognosticbiomarkerinhepatocellularcarcinoma
AT nieyongzhan anintegrativeanalysisrevealingcuproptosisrelatedlncrnassignatureasanovelprognosticbiomarkerinhepatocellularcarcinoma
AT fandaiming anintegrativeanalysisrevealingcuproptosisrelatedlncrnassignatureasanovelprognosticbiomarkerinhepatocellularcarcinoma
AT wukaichun anintegrativeanalysisrevealingcuproptosisrelatedlncrnassignatureasanovelprognosticbiomarkerinhepatocellularcarcinoma
AT xialimin anintegrativeanalysisrevealingcuproptosisrelatedlncrnassignatureasanovelprognosticbiomarkerinhepatocellularcarcinoma
AT chenxilang integrativeanalysisrevealingcuproptosisrelatedlncrnassignatureasanovelprognosticbiomarkerinhepatocellularcarcinoma
AT sunmengyu integrativeanalysisrevealingcuproptosisrelatedlncrnassignatureasanovelprognosticbiomarkerinhepatocellularcarcinoma
AT fengweibo integrativeanalysisrevealingcuproptosisrelatedlncrnassignatureasanovelprognosticbiomarkerinhepatocellularcarcinoma
AT chenjie integrativeanalysisrevealingcuproptosisrelatedlncrnassignatureasanovelprognosticbiomarkerinhepatocellularcarcinoma
AT jixiaoyu integrativeanalysisrevealingcuproptosisrelatedlncrnassignatureasanovelprognosticbiomarkerinhepatocellularcarcinoma
AT xiemeng integrativeanalysisrevealingcuproptosisrelatedlncrnassignatureasanovelprognosticbiomarkerinhepatocellularcarcinoma
AT huangwenjie integrativeanalysisrevealingcuproptosisrelatedlncrnassignatureasanovelprognosticbiomarkerinhepatocellularcarcinoma
AT chenxiaoping integrativeanalysisrevealingcuproptosisrelatedlncrnassignatureasanovelprognosticbiomarkerinhepatocellularcarcinoma
AT zhangbixiang integrativeanalysisrevealingcuproptosisrelatedlncrnassignatureasanovelprognosticbiomarkerinhepatocellularcarcinoma
AT nieyongzhan integrativeanalysisrevealingcuproptosisrelatedlncrnassignatureasanovelprognosticbiomarkerinhepatocellularcarcinoma
AT fandaiming integrativeanalysisrevealingcuproptosisrelatedlncrnassignatureasanovelprognosticbiomarkerinhepatocellularcarcinoma
AT wukaichun integrativeanalysisrevealingcuproptosisrelatedlncrnassignatureasanovelprognosticbiomarkerinhepatocellularcarcinoma
AT xialimin integrativeanalysisrevealingcuproptosisrelatedlncrnassignatureasanovelprognosticbiomarkerinhepatocellularcarcinoma